[
  {
    "ts": "2026-02-18T02:21:20+00:00",
    "headline": "This State Has More Millionaires Per Capita Than Any Other",
    "summary": "There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That’s a fancy way of saying that prosperity is concentrated in some U.S. states more than in others. As a result, a handful of America’s 50 states have more millionaires than others. By the process ... This State Has More Millionaires Per Capita Than Any Other",
    "url": "https://247wallst.com/investing/2026/02/17/this-state-has-more-millionaires-per-capita-than-any-other/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c78046f0-1ca5-32dc-85cf-6f8c38a5db54",
      "content": {
        "id": "c78046f0-1ca5-32dc-85cf-6f8c38a5db54",
        "contentType": "STORY",
        "title": "This State Has More Millionaires Per Capita Than Any Other",
        "description": "",
        "summary": "There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That’s a fancy way of saying that prosperity is concentrated in some U.S. states more than in others. As a result, a handful of America’s 50 states have more millionaires than others. By the process ... This State Has More Millionaires Per Capita Than Any Other",
        "pubDate": "2026-02-18T02:21:20Z",
        "displayTime": "2026-02-18T02:21:20Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/f7109cc114790579cb27b509e454b2fa",
          "originalWidth": 2560,
          "originalHeight": 1707,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BsdaEb1kKl4fYOmiuFHAbQ--~B/aD0xNzA3O3c9MjU2MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/24_7_wall_st__718/f7109cc114790579cb27b509e454b2fa.cf.webp",
              "width": 2560,
              "height": 1707,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.yBu0G0aPHwBbKcaFQSnrA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/f7109cc114790579cb27b509e454b2fa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/02/17/this-state-has-more-millionaires-per-capita-than-any-other/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/state-more-millionaires-per-capita-022120447.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T08:06:29+00:00",
    "headline": "The Patent Cliff Is a Hill: Why Merck's Diversification Engine Makes MRK a Buy",
    "summary": "Diversification Beyond the Keytruda Cliff",
    "url": "https://finance.yahoo.com/news/patent-cliff-hill-why-mercks-080629498.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "35ef5253-eb9f-332e-ac8c-83adc750f78c",
      "content": {
        "id": "35ef5253-eb9f-332e-ac8c-83adc750f78c",
        "contentType": "STORY",
        "title": "The Patent Cliff Is a Hill: Why Merck's Diversification Engine Makes MRK a Buy",
        "description": "",
        "summary": "Diversification Beyond the Keytruda Cliff",
        "pubDate": "2026-02-18T08:06:29Z",
        "displayTime": "2026-02-18T08:06:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/patent-cliff-hill-why-mercks-080629498.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/patent-cliff-hill-why-mercks-080629498.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T10:16:00+00:00",
    "headline": "$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)",
    "summary": "The global active pharmaceutical ingredients (API) market is poised to reach USD 198.39 billion by 2030, witnessing a CAGR of 6.6% from USD 144.20 billion in 2025. The API market's growth is significantly driven by expanding oncology, rare disease, and diabetes pipelines, bolstered by peptide-based drugs like Semaglutide. In 2024, the pharmaceutical and biotechnology segment captured the largest market share, reinforced by in-house manufacturing of high-value drugs and increasing outsourcing for",
    "url": "https://finance.yahoo.com/news/198-39-bn-active-pharmaceutical-101600490.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "667d5d85-1890-3c02-8e2b-8151284ca38a",
      "content": {
        "id": "667d5d85-1890-3c02-8e2b-8151284ca38a",
        "contentType": "STORY",
        "title": "$198.39 Bn Active Pharmaceutical Ingredients (API) Markets, 2030 by Synthesis (synthetic, Biotech), Potency (HPAPI), Product (mAbs, Hormones), Drug (OTC, Rx), Application (Diabetes, Oncology)",
        "description": "",
        "summary": "The global active pharmaceutical ingredients (API) market is poised to reach USD 198.39 billion by 2030, witnessing a CAGR of 6.6% from USD 144.20 billion in 2025. The API market's growth is significantly driven by expanding oncology, rare disease, and diabetes pipelines, bolstered by peptide-based drugs like Semaglutide. In 2024, the pharmaceutical and biotechnology segment captured the largest market share, reinforced by in-house manufacturing of high-value drugs and increasing outsourcing for",
        "pubDate": "2026-02-18T10:16:00Z",
        "displayTime": "2026-02-18T10:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/f17019bd7ddea4815dee288c80d9b7fe",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Active Pharmaceutical Ingredients (API) Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/82uh4eZvFTWMRxmA7hFB.Q--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f17019bd7ddea4815dee288c80d9b7fe.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/weD1LQLKgiMB6mDCx2zL8A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/f17019bd7ddea4815dee288c80d9b7fe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/198-39-bn-active-pharmaceutical-101600490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/198-39-bn-active-pharmaceutical-101600490.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "TEVA"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T11:45:00+00:00",
    "headline": "Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine",
    "summary": "RAHWAY, N.J., & ROCHESTER, Minn., February 18, 2026--Merck and Mayo Clinic today announced a R&D agreement to apply artificial intelligence (AI), advanced analytics and data to support drug discovery.",
    "url": "https://finance.yahoo.com/news/merck-mayo-clinic-announce-research-114500310.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "7e09b530-9654-390a-883f-36a81af578a8",
      "content": {
        "id": "7e09b530-9654-390a-883f-36a81af578a8",
        "contentType": "STORY",
        "title": "Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine",
        "description": "",
        "summary": "RAHWAY, N.J., & ROCHESTER, Minn., February 18, 2026--Merck and Mayo Clinic today announced a R&D agreement to apply artificial intelligence (AI), advanced analytics and data to support drug discovery.",
        "pubDate": "2026-02-18T11:45:00Z",
        "displayTime": "2026-02-18T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/716a3574f3252f3adb867c7074c30b14",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IzXLL73YPVEVavNKEpSaCw--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/716a3574f3252f3adb867c7074c30b14.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7dN6iDWbc13FegoA1rkXBQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/716a3574f3252f3adb867c7074c30b14.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mayo-clinic-announce-research-114500310.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mayo-clinic-announce-research-114500310.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T15:17:10+00:00",
    "headline": "Merck & Co. (MRK) Advances on Robust Keytruda Sales and Positive Clinical Trial Results",
    "summary": "Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile during the quarter amid concerns over elevated valuations and financing for large-scale data center investments, although the portfolio modestly outperformed the Russell 1000 benchmark […]",
    "url": "https://finance.yahoo.com/news/merck-co-mrk-advances-robust-151710546.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "7cd8ee98-f92a-32e1-ab3b-fa5b7f286874",
      "content": {
        "id": "7cd8ee98-f92a-32e1-ab3b-fa5b7f286874",
        "contentType": "STORY",
        "title": "Merck & Co. (MRK) Advances on Robust Keytruda Sales and Positive Clinical Trial Results",
        "description": "",
        "summary": "Impax Asset Management‘s “Impax US Sustainable Economy Fund” released its Q4 2025 investor letter. A copy of the letter can be downloaded here. The fund reported that equity markets remained volatile during the quarter amid concerns over elevated valuations and financing for large-scale data center investments, although the portfolio modestly outperformed the Russell 1000 benchmark […]",
        "pubDate": "2026-02-18T15:17:10Z",
        "displayTime": "2026-02-18T15:17:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/f4f6ab0951c1038aa2303274fb6c0b9d",
          "originalWidth": 1280,
          "originalHeight": 853,
          "caption": "Merck & Co., Inc. (MRK) Advances on Robust Keytruda Sales and Positive Clinical Trial Results",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OdUZhzJneaC3psvAqDZt0Q--~B/aD04NTM7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/f4f6ab0951c1038aa2303274fb6c0b9d.cf.webp",
              "width": 1280,
              "height": 853,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/igPuOk294DrUoWTvXb9e3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/f4f6ab0951c1038aa2303274fb6c0b9d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-mrk-advances-robust-151710546.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-co-mrk-advances-robust-151710546.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T16:20:43+00:00",
    "headline": "Moderna stock surges as FDA reverses course, agrees to review new flu shot",
    "summary": "Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.",
    "url": "https://finance.yahoo.com/news/moderna-stock-surges-as-fda-reverses-course-agrees-to-review-new-flu-shot-162043049.html",
    "source": "Yahoo Finance",
    "provider": "yfinance",
    "raw": {
      "id": "4cfb8bc3-ca49-4baf-a920-85e6cc67bbe6",
      "content": {
        "id": "4cfb8bc3-ca49-4baf-a920-85e6cc67bbe6",
        "contentType": "STORY",
        "title": "Moderna stock surges as FDA reverses course, agrees to review new flu shot",
        "description": "",
        "summary": "Moderna stock jumped more than 6% after the FDA agreed to review the drugmaker's first flu shot of the season, reversing course on a decision to reject the review last week.",
        "pubDate": "2026-02-18T16:20:43Z",
        "displayTime": "2026-02-18T16:20:43Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2026-02/3002f2b0-0ccb-11f1-bdfb-e432c78a6bb6",
          "originalWidth": 4664,
          "originalHeight": 2624,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WmZ3_wvN4V2p.UvvH..bWA--~B/aD0yNjI0O3c9NDY2NDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2026-02/3002f2b0-0ccb-11f1-bdfb-e432c78a6bb6.cf.webp",
              "width": 4664,
              "height": 2624,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/x4r4v1r90jztIkaJCsEL_Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2026-02/3002f2b0-0ccb-11f1-bdfb-e432c78a6bb6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance",
          "url": "http://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-stock-surges-as-fda-reverses-course-agrees-to-review-new-flu-shot-162043049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-stock-surges-as-fda-reverses-course-agrees-to-review-new-flu-shot-162043049.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BNTX"
            },
            {
              "symbol": "AZN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T16:03:00+00:00",
    "headline": "Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ Drugs - Collaborations and Licensing by Key Players Like Moderna, Merck, and IO Biotech",
    "summary": "The cancer vaccine market presents opportunities in personalized and therapeutic vaccines, innovations in delivery strategies, and combination therapies. Collaborations and licensing by key players like Moderna, Merck, and IO Biotech drive industry progression. Challenges remain in broadening efficacy and optimizing delivery platforms.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The \"Cancer Vaccines - Competitive Landscape, 2026\" has been added to ResearchAndMarkets.com's offering. This report offe",
    "url": "https://finance.yahoo.com/news/cancer-vaccines-competitive-landscape-report-160300672.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "3f4a0bc7-63c6-3efa-8e10-343560fcf25b",
      "content": {
        "id": "3f4a0bc7-63c6-3efa-8e10-343560fcf25b",
        "contentType": "STORY",
        "title": "Cancer Vaccines Competitive Landscape Report 2026: Comprehensive Insights About 250+ Companies and 300+ Drugs - Collaborations and Licensing by Key Players Like Moderna, Merck, and IO Biotech",
        "description": "",
        "summary": "The cancer vaccine market presents opportunities in personalized and therapeutic vaccines, innovations in delivery strategies, and combination therapies. Collaborations and licensing by key players like Moderna, Merck, and IO Biotech drive industry progression. Challenges remain in broadening efficacy and optimizing delivery platforms.Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The \"Cancer Vaccines - Competitive Landscape, 2026\" has been added to ResearchAndMarkets.com's offering. This report offe",
        "pubDate": "2026-02-18T16:03:00Z",
        "displayTime": "2026-02-18T16:03:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cancer-vaccines-competitive-landscape-report-160300672.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cancer-vaccines-competitive-landscape-report-160300672.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "IOBT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T16:58:50+00:00",
    "headline": "XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning",
    "summary": "SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) exists to solve a specific problem: how do you gain broad exposure to pharmaceutical companies without the concentration risk of the largest healthcare names dominating your returns? XPH holds 57 positions with relatively even weighting—no single stock exceeds 2.12% of the portfolio. That structure delivers pure-play pharma exposure spanning large-cap ... XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning",
    "url": "https://247wallst.com/investing/2026/02/18/xphs-29-run-looks-tempting-but-the-5y-chart-is-a-warning/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "9a3aa9b5-91fb-3b88-a12f-9dd342bf3b70",
      "content": {
        "id": "9a3aa9b5-91fb-3b88-a12f-9dd342bf3b70",
        "contentType": "STORY",
        "title": "XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning",
        "description": "",
        "summary": "SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) exists to solve a specific problem: how do you gain broad exposure to pharmaceutical companies without the concentration risk of the largest healthcare names dominating your returns? XPH holds 57 positions with relatively even weighting—no single stock exceeds 2.12% of the portfolio. That structure delivers pure-play pharma exposure spanning large-cap ... XPH’s 29% Run Looks Tempting, But The 5y Chart Is A Warning",
        "pubDate": "2026-02-18T16:58:50Z",
        "displayTime": "2026-02-18T16:58:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/2e8d8fe3b8570889f9c883618ec756b9",
          "originalWidth": 1500,
          "originalHeight": 843,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JbPCO8FOrm0b605uaDn2ng--~B/aD04NDM7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/2e8d8fe3b8570889f9c883618ec756b9.cf.webp",
              "width": 1500,
              "height": 843,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A74.Wa1qSoFycszCKGok4w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/2e8d8fe3b8570889f9c883618ec756b9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/02/18/xphs-29-run-looks-tempting-but-the-5y-chart-is-a-warning/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/xph-29-run-looks-tempting-165850994.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "XPH"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-18T21:11:15+00:00",
    "headline": "Merck (MRK) Valuation Check As Keytruda SC Approval And Mayo Clinic AI Deal Shape Growth Story",
    "summary": "Merck (MRK) is back in focus after Health Canada cleared KEYTRUDA SC, a subcutaneous version of its flagship cancer therapy, alongside a new AI-focused drug discovery partnership with Mayo Clinic that highlights its research ambitions. See our latest analysis for Merck. Those approvals and AI partnerships sit against a strong run in the shares, with Merck’s 30 day share price return of 11.71% and 90 day share price return of 27.90% pointing to building momentum. At the same time, the 1 year...",
    "url": "https://finance.yahoo.com/news/merck-mrk-valuation-check-keytruda-211115996.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "d39ef26e-3c3f-3586-848d-d951ad687e23",
      "content": {
        "id": "d39ef26e-3c3f-3586-848d-d951ad687e23",
        "contentType": "STORY",
        "title": "Merck (MRK) Valuation Check As Keytruda SC Approval And Mayo Clinic AI Deal Shape Growth Story",
        "description": "",
        "summary": "Merck (MRK) is back in focus after Health Canada cleared KEYTRUDA SC, a subcutaneous version of its flagship cancer therapy, alongside a new AI-focused drug discovery partnership with Mayo Clinic that highlights its research ambitions. See our latest analysis for Merck. Those approvals and AI partnerships sit against a strong run in the shares, with Merck’s 30 day share price return of 11.71% and 90 day share price return of 27.90% pointing to building momentum. At the same time, the 1 year...",
        "pubDate": "2026-02-18T21:11:15Z",
        "displayTime": "2026-02-18T21:11:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-valuation-check-keytruda-211115996.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-mrk-valuation-check-keytruda-211115996.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]